Effectiveness of DNAtrix’s DNX-2440 Oncolytic Virus Expressing OX40L in Solid Tumors to be Presented at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer
Houston, TX – November 7, 2018 – DNAtrix, a leader in oncolytic virus immunotherapies for cancer, announced today that MD Anderson Cancer Center collaborator, Juan Fueyo, MD, will present preclinical results for DNX-2440, an armed oncolytic adenovirus that expresses OX40 ligand (OX40L) in infected tumor cells, at the upcoming 2018 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, DC from November 7th - 11th.
Treatment of syngeneic tumors in a B16F10 melanoma model with murine DNX-2440 (a.k.a. Delta-24-RGDOX) led to prolonged survival, inhibition of injected tumors, and an abscopal effect for untreated tumors. Surviving mice treated with DNX-2440 demonstrated immune memory when rechallenged.
“We are encouraged by these striking results in solid tumors,” said Frank Tufaro, PhD, CEO of DNAtrix. “DNX-2440 is now in clinical trials for glioblastoma and will be entering the clinic shortly for solid tumors. We are eager to see how these results translate to the clinical setting to provide a benefit for patients.”
Details of the presentations are as follows:
Localized treatment with oncolytic adenovirus Delta-24-RGDOX elicits efficacious abscopal immunity against disseminated melanomas
Abstract Number: P605
Presenter: Hong Jiang, PhD
Forced expression of OX40L and inhibition of IDO within the murine glioblastoma tumor microenvironment creates a potent anti-tumor immune response
Abstract Number: P370
Presenter: Teresa Nguyen
To access the recently published paper on DNX-2440, visit the Cancer Research website http://cancerres.aacrjournals.org/content/77/14/3894.long.
For more information about ongoing DNAtrix clinical studies, visit the ClinicalTrials.gov website: NCT03714334 (DNX-2440 for recurrent glioblastoma), NCT02798406 (DNX-2401 + pembrolizumab for recurrent glioblastoma), and NCT03178032 (DNX-2401 for newly diagnosed pediatric diffuse intrinsic pontine glioma, DIPG).
DNAtrix is a privately held, clinical stage, biopharmaceutical company developing oncolytic virus immunotherapies for cancer. Its oncolytic adenovirus platform viruses initiate a chain reaction of tumor cell killing by selectively replicating within cancer cells (but not normal cells), triggering an immune response directed against tumors. DNAtrix has multiple virus candidates in clinical trials for cancers with urgent need for novel approaches. The company’s investors include Morningside Ventures and Mercury Fund. For more information, please visit the company website at http://www.DNAtrix.com.
Imran Alibhai, PhD
SVP Business Development